Has Mark Callender received payments from drug or device companies?

Yes. Drug and device makers reported $3,898 in general payments to Mark Callender across 189 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Callender did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Callender come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Callender

Physician Assistant · Slidell, LANPI 1942406616

Payments from drug & device makers

$3,898in general payments, 2019–2025

Across 189 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$634
Sanofi$630
Regeneron Healthcare Solutions, Inc.$421
Johnson & Johnson$414
Galderma Laboratories, L.p.$285
UCB, Inc.$272
plus $1K from 16 others

What the payments were for

Food & beverage$3,44588%
Education$45412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	35	$634
Sanofi	32	$630
Regeneron Healthcare Solutions, Inc.	16	$421
Johnson & Johnson	16	$414
Galderma Laboratories, L.p.	20	$285
UCB, Inc.	13	$272
LEO Pharma Inc.	11	$228
AbbVie	9	$198
Amgen	7	$150
Verrica Pharmaceuticals Inc.	4	$92
Pfizer	4	$89
Incyte Corporation	4	$82
Sanofi-aventis U.S. LLC	1	$72
Ortho Dermatologics, A Division Of Bausch Health US, LLC	4	$68
Novartis	2	$45
Medimetriks Pharmaceuticals, Inc.	2	$43
Almirall LLC	2	$41
LNHC, Inc	2	$39
Organon	2	$31
Lilly USA, LLC	1	$28
Sun Pharmaceutical Industries Inc.	1	$19
Organogenesis Inc.	1	$18

How this compares

$3,898 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana →

Medicare billing

Part B allowed, 2024

$13,921

Medicare patients

Services billed

395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluorouracil	18	$851
Ketoconazole	53	$671
CiclopiroxCiclopirox Olamine	20	$617
Triamcinolone Acetonide	73	$576
Clobetasol Propionate	23	$450
Clindamycin Phosphate	14	$277
Hydrocortisone	41	$162
Mupirocin	19	$158
Doxycycline Monohydrate	11	$78

Paid to pharmacies, not to this prescriber.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other physician assistant in Slidell